Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarducci, Cristina, Bonechi, Martina, Benelli, Matteo, Biagioni, Chiara, Boccalini, Giulia, Romagnoli, Dario, Verardo, Roberto, Schiff, Rachel, Osborne, C. Kent, De Angelis, Carmine, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261939/
https://www.ncbi.nlm.nih.gov/pubmed/30511015
http://dx.doi.org/10.1038/s41523-018-0092-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261939/
https://www.ncbi.nlm.nih.gov/pubmed/30511015
http://dx.doi.org/10.1038/s41523-018-0092-4

Ejemplares similares